Generation of human iPS cells by chemically defined conditions
通过化学定义的条件生成人类 iPS 细胞
基本信息
- 批准号:8278976
- 负责人:
- 金额:$ 21.92万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2010
- 资助国家:美国
- 起止时间:2010-09-17 至 2015-08-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (provided by applicant): Although stem cells hold considerable promises for the treatment of a number of devastating diseases (e.g. cardiovascular diseases, neurodegenerative diseases, diabetes and cancers), obstacles such as control of stem cell fate/function, immuno-rejection, and limited cell sources must be overcome before their therapeutic potentials can be realized. Recent studies have suggested that tissue-specific somatic cells may overcome their intrinsic lineage-restriction to de-differentiate or trans-differentiate (i.e. reprogramming) upon exposure to a specific set of signals (or ectopic expression of master transcription factors) in vitro and in vivo. Reprogramming of various rodent and human somatic cells to pluripotent ESC-like cells (i.e. induced pluripotent/iPS cells) has recently been achieved by viral transduction of four transcription factors (e.g. Oct4, cMyc, Sox2 and Klf4). More recently, we have reported that small molecules can replace certain transcription factors as well as substantially improve reprogramming efficiency and kinetics in generating iPS cells, and developed a method of generating and using recombinant cell-penetrating proteins to generate iPS cells without using any genetic materials and genetic manipulation (please see our preliminary results). With those proof-of-principle demonstrations, we propose to further develop/optimize the chemically defined, protein and small molecule-based reprogramming process in human cells to have highly robust and efficient method and to further in-depth characterize those cells.
PUBLIC HEALTH RELEVANCE: Reprogramming of various rodent and human somatic cells to pluripotent ESC-like cells (i.e. induced pluripotent/iPS cells) has recently been achieved by viral transduction of four transcription factors (e.g. Oct4, cMyc, Sox2 and Klf4). More recently, we have reported that small molecules can replace certain transcription factors as well as substantially improve reprogramming efficiency and kinetics in generating iPS cells, and developed a method of generating and using recombinant cell-penetrating proteins to generate iPS cells without using any genetic materials and genetic manipulation (please see our preliminary results). With those proof-of-principle demonstrations, we propose to further develop/optimize the chemically defined, protein and small molecule-based reprogramming process in human cells to have highly robust and efficient method and to further in-depth characterize those cells. Collectively, the studies described in this proposal will provide novel chemical tools for producing unlimited amount of (autologous) pluripotent cells from differentiated/lineage-restricted cells for various applications as well as studying the underlying molecular mechanisms of pluripotency and epigenetic regulations, and may ultimately facilitate development of small molecule therapeutics to treat human diseases and stimulate tissue/organ regeneration in vivo.
描述(由申请人提供):尽管干细胞对多种毁灭性疾病的治疗(例如心血管疾病,神经退行性疾病,糖尿病和癌症)的治疗有很大的承诺,但是诸如干细胞命运/功能的控制,限制细胞的障碍必须在其更具范围的潜在范围之前实现。最近的研究表明,组织特异性的体细胞可以在暴露于特定的信号(或主转录因子的异位表达)时,可以克服其内在的谱系限制,以去分化或反差异(即重编程)。 最近通过病毒转导四个转录因子(例如Oct4,Cmyc,Sox2和Klf4)来实现各种啮齿动物和人体细胞对多能ESC样细胞(即诱导多能/IPS细胞)的重编程。最近,我们报告说,小分子可以替代某些转录因子,并在产生IPS细胞时实质上提高了重编程效率和动力学,并开发了一种生成和使用重组细胞培训蛋白来生成IPS细胞的方法,以生成IPS细胞,而无需使用任何遗传材料和遗传操纵(请参阅我们的初步结果)。通过这些原则证明,我们建议在人类细胞中进一步开发/优化基于化学定义的,蛋白质和基于小分子的重编程过程,以具有高度鲁棒和有效的方法,并进一步深入地表征这些细胞。
公共卫生相关性:最近通过病毒转导四个转录因子(例如OCT4,CMYC,SOX2和KLF4)来实现各种啮齿动物和人类体细胞对多能ESC样细胞(即诱导多能/IPS细胞)的重编程。最近,我们报告说,小分子可以替代某些转录因子,并在产生IPS细胞时实质上提高了重编程效率和动力学,并开发了一种生成和使用重组细胞培训蛋白来生成IPS细胞的方法,以生成IPS细胞,而无需使用任何遗传材料和遗传操纵(请参阅我们的初步结果)。通过这些原则证明,我们建议在人类细胞中进一步开发/优化基于化学定义的,蛋白质和基于小分子的重编程过程,以具有高度鲁棒和有效的方法,并进一步深入地表征这些细胞。 总的来说,该提案中描述的研究将提供新的化学工具,用于从分化/谱系限制的细胞中生产无数量的(自体)多能细胞,以用于各种应用,并研究多能性和表观远期法规的潜在分子机制,并可能最终促进小分子的构造和刺激人类疾病的发展。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
SHENG DING其他文献
SHENG DING的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('SHENG DING', 18)}}的其他基金
Generation of human iPS cells by chemically defined conditions
通过化学定义的条件生成人类 iPS 细胞
- 批准号:
8145688 - 财政年份:2010
- 资助金额:
$ 21.92万 - 项目类别:
Generation of human iPS cells by chemically defined conditions
通过化学定义的条件生成人类 iPS 细胞
- 批准号:
8727310 - 财政年份:2010
- 资助金额:
$ 21.92万 - 项目类别:
Regeneration of Retinal Neurons by Chemically Induced Reprogramming of Muller Gli
通过化学诱导 Muller Gli 重编程实现视网膜神经元再生
- 批准号:
8730661 - 财政年份:2010
- 资助金额:
$ 21.92万 - 项目类别:
Generation of human iPS cells by chemically defined conditions
通过化学定义的条件生成人类 iPS 细胞
- 批准号:
8335198 - 财政年份:2010
- 资助金额:
$ 21.92万 - 项目类别:
Generation of human iPS cells by chemically defined conditions
通过化学定义的条件生成人类 iPS 细胞
- 批准号:
7863654 - 财政年份:2010
- 资助金额:
$ 21.92万 - 项目类别:
Generation of human iPS cells by chemically defined conditions
通过化学定义的条件生成人类 iPS 细胞
- 批准号:
8531713 - 财政年份:2010
- 资助金额:
$ 21.92万 - 项目类别:
Regeneration of Retinal Neurons by Chemically Induced Reprogramming of Muller Gli
通过化学诱导 Muller Gli 重编程实现视网膜神经元再生
- 批准号:
8538981 - 财政年份:2010
- 资助金额:
$ 21.92万 - 项目类别:
Regeneration of Retinal Neurons by Chemically Induced Reprogramming of Muller Gli
通过化学诱导 Muller Gli 重编程实现视网膜神经元再生
- 批准号:
8145614 - 财政年份:2010
- 资助金额:
$ 21.92万 - 项目类别:
相似国自然基金
人类ACE2变构抑制剂的成药性及其抗广谱冠状病毒感染的机制研究
- 批准号:82330111
- 批准年份:2023
- 资助金额:220 万元
- 项目类别:重点项目
PHACTR4重要变异通过磷酸酶PP1参与人类神经管畸形发生的机制研究
- 批准号:82301930
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
通往人类智能增强:医疗场景中以人为中心的人智交互设计及其效果研究
- 批准号:72301279
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
人地系统耦合下脱贫地区生态系统服务与人类福祉的互馈机制与模拟:以环京津贫困带为例
- 批准号:42371300
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
基于人类血清素神经元报告系统研究TSPYL1突变对婴儿猝死综合征的致病作用及机制
- 批准号:82371176
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
相似海外基金
Generation of the transplantation model of human iPS cell-derived airway epithelial sheet into nasal cavity
人iPS细胞来源的气道上皮片鼻腔移植模型的建立
- 批准号:
23K08961 - 财政年份:2023
- 资助金额:
$ 21.92万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Development of human organ generation technology recapitulating microgravity environment
再现微重力环境的人体器官生成技术开发
- 批准号:
23K11806 - 财政年份:2023
- 资助金额:
$ 21.92万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Generation of novel human ACTH cells and their application to the treatment of pituitary intractable diseases
新型人ACTH细胞的产生及其在垂体疑难杂症治疗中的应用
- 批准号:
22K08657 - 财政年份:2022
- 资助金额:
$ 21.92万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Custom generation of human brain cells: establishment of in vitro differentiation system for whole cell types
人脑细胞的定制生成:全细胞类型体外分化系统的建立
- 批准号:
22K18388 - 财政年份:2022
- 资助金额:
$ 21.92万 - 项目类别:
Grant-in-Aid for Challenging Research (Pioneering)
Generation of bladder urothelium sheets consisting of human induced pluripotent stem cell-derived urothelial cells
由人诱导多能干细胞衍生的尿路上皮细胞组成的膀胱尿路上皮片的生成
- 批准号:
20K18115 - 财政年份:2022
- 资助金额:
$ 21.92万 - 项目类别:
Grant-in-Aid for Early-Career Scientists